Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.
Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.
Fate Therapeutics (NASDAQ:FATE) will present preliminary clinical data for its off-the-shelf CAR T-cell candidate FT819 in systemic sclerosis (SSc) at the ISSCR 2026 Annual Meeting in Montréal, July 8-11, 2026.
The Phase 1 basket trial SSc arm includes treatment-refractory patients, some with up to 15 years of disease. Early data from four patients show rCRISS ≥25 and meaningful mean mRSS improvement at 3 months, with no CRS, ICANS, GvHD, hypogammaglobulinemia, or deaths reported.
Fate Therapeutics (NASDAQ:FATE) announced management participation in several third quarter 2026 investor conferences focused on healthcare and therapeutics.
Events include forums hosted by Leerink Partners, Wells Fargo, Cantor Fitzgerald, and H.C. Wainwright, with potential presentations or fireside chats and webcasts available through the company’s investor relations website.
Fate Therapeutics (NASDAQ:FATE) appointed industry veteran Laura Hamill to its Board of Directors as the company advances its iPSC-derived cell therapy pipeline toward commercialization.
Hamill brings over 30 years of commercial leadership, including roles overseeing about $22 billion in annual revenue and organizations of up to 2,500 employees.
Fate Therapeutics (NASDAQ:FATE) presented new data on its off-the-shelf CAR T-cell candidates FT819 and FT839 at EULAR 2026.
FT819 has treated 21 refractory SLE patients, showing favorable tolerability, deep B-cell depletion, improved disease activity scores, and reduced glucocorticoid use. Preclinical FT839 data showed selective elimination of activated immune cells in rheumatoid arthritis samples without conditioning chemotherapy.
Fate Therapeutics (NASDAQ:FATE) granted new employee equity awards under Nasdaq Listing Rule 5635(c)(4).
On June 1, 2026, two newly hired non-executive employees received RSUs covering 67,300 common shares under the company’s Amended and Restated Inducement Equity Plan, vesting over four years in 25% annual installments.
Fate Therapeutics (NASDAQ:FATE) reported preliminary Phase 1 data for off-the-shelf CAR T-cell candidate FT836 in advanced solid tumors at ASCO 2026.
According to Fate Therapeutics, FT836 showed a favorable safety profile, trafficking and persistence without conditioning chemotherapy, and early anti-tumor activity in heavily pre-treated KRASwt metastatic colorectal cancer patients.
Fate Therapeutics (NASDAQ:FATE) will present new data from its off-the-shelf, iPSC-derived CAR T-cell therapy pipeline for cancer and autoimmune diseases at the 2026 ASCO and EULAR annual meetings.
Presentations cover product candidates FT836 for solid tumors and FT819/FT839 for lupus and other autoimmune diseases, with Phase 1 safety and efficacy results highlighted.
Fate Therapeutics (NASDAQ:FATE) reported first quarter 2026 results and pipeline progress. Revenue was $1.3 million, with total operating expenses of $34.3 million, and cash, cash equivalents and investments of $174.8 million, extending operating runway into 2028.
The company plans to start RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in refractory SLE with lupus nephritis in 2H 2026, while advancing FT819, FT839 and FT836 clinical programs and benefiting from FDA CDRP and RMAT designations.
Fate Therapeutics (NASDAQ:FATE) is presenting new data on its off-the-shelf CAR T-cell therapies FT819, FT839, and FT836 at the 2026 ASGCT meeting.
FT819 Phase 1 SLE data show clinical responses without conditioning chemotherapy; FT839 and FT836 preclinical results demonstrate broad immune-cell targeting and tumor control with Sword and Shield™ engineering.
Fate Therapeutics (NASDAQ: FATE) said the FDA selected its off-the-shelf iPSC-derived anti-CD19 CAR T candidate FT819 for the CMC Development and Readiness Pilot (CDRP) program to support manufacturing readiness for SLE with lupus nephritis.
Selection and existing RMAT designation aim to accelerate CMC engagement and help align manufacturing readiness with a planned Phase 2 potentially registrational trial.